TOP N53
Alternative Names: TOP-N-53Latest Information Update: 25 Jun 2026
At a glance
- Originator Topadur Pharma
- Class Antiulcers; Foot disorder therapies; Skin disorder therapies; Small molecules
- Mechanism of Action Nitric oxide donors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Yes - Skin ulcer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Skin ulcer
- Phase I Diabetic foot ulcer
- Preclinical Alopecia
Most Recent Events
- 18 Jun 2026 Preclinical trials in Alopecia in Switzerland (unspecified route) (TOPADUR Pharma pipeline, June 2026)
- 09 Sep 2025 TOP N53 receives Orphan Drug status for Skin ulcer in USA
- 28 Nov 2023 Phase-I clinical development in Diabetic foot ulcer (In volunteers) is ongoing in Switzerland (SC) (Topadur Pharma pipeline, November 2023)